cdk 4/6 inhibitors for patients with recurrent er /her2- breast cancer: 2023 best of breast
Published 1 year ago • 309 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
26:08
metastatic hormone positive breast cancer | 2023 ku breast cancer year in review conference
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
1:20
dr. finn on new cdk 4/6 inhibitors for breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
1:36
dr. mahtani on the use of cdk 4/6 inhibitors in metastatic er breast cancer
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
0:37
cdk4/6 inhibitors in her2-negative breast cancer based on phase iii monaleesa-7 trial
-
6:28
cdk4/6 inhibitors: managing toxicity in hr mbc
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
1:51
reflecting on the use of cdk4/6 inhibitors in hr breast cancer
-
4:45
cdk4/6 inhibitors for hr metastatic breast cancer
-
1:00
dr. tolaney on remaining questions with cdk4/6 inhibitors in hr /her2- breast cancer
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
5:56
cdk 4/6 inhibitors for older women with hr-positive breast cancer
-
21:11
current clinical data for cdk 4/6 inhibitors in breast cancer
-
8:55
cdk4/6 inhibitors in hr metastatic breast cancer